Tolterodine

Tolterodine
Clinical data
Trade namesDetrol, Detrusitol, others
Other namesPNU-200583E
AHFS/Drugs.comMonograph
MedlinePlusa699026
License data
Pregnancy
category
  • AU: B3
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability77%
Protein bindingApproximately 96.3%
Elimination half-life1.9–3.7 hours
Identifiers
  • (S)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-methylphenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.232.068
Chemical and physical data
FormulaC22H31NO
Molar mass325.496 g·mol−1
3D model (JSmol)
  • Cc1ccc(c(c1)[C@H](CCN(C(C)C)C(C)C)c2ccccc2)O
  • InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1 Y
  • Key:OOGJQPCLVADCPB-HXUWFJFHSA-N Y
  (verify)

Tolterodine, sold under the brand name Detrol among others, is a medication used to treat frequent urination, urinary incontinence, or urinary urgency. Effects are seen within an hour. It is taken by mouth.

Common side effects include headache, dry mouth, constipation, and dizziness. Serious side effects may include angioedema, urinary retention, and QT prolongation. Use in pregnancy and breastfeeding are of unclear safety. It works by blocking muscarinic receptors in the bladder thus decreasing bladder contractions.

Tolterodine was approved for medical use in 1998. It is available as a generic medication. In 2020, it was the 271st most commonly prescribed medication in the United States, with more than 1 million prescriptions.